Categories: News

cbdMD Launches Max Chill Dragon Fruit D9 Gummies: Your Go-To Relaxation Blend for the Summer

Charlotte, North Carolina–(Newsfile Corp. – May 16, 2024) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) a leading name in premium CBD offerings, is excited to introduce its newest relaxation innovation: “Max Chill” Dragon Fruit D9 Gummies. Crafted to elevate your summer unwind sessions, these gummies boast a distinctive 1:1 CBD to THC ratio, marking a milestone in the brand’s selection of high-mg THC products.

Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, ensuring a balanced experience. This equal ratio harnesses the synergy between THC and CBD to maximize relaxation benefits. CBD’s ability to promote relaxation and counteract potential negative sensations associated with THC makes the combination ideal for unwinding and relieving daily stress.

“At cbdMD, we’re committed to continually enhancing our customers’ journeys, and this new product epitomizes that commitment,” expressed Ronan Kennedy, CEO at cbdMD. “We formulated this product with a specific goal in mind: to offer a Farm Bill compliant high mg THC product designed to help reduce daily stress and promote relaxation.”

Key Highlights of Max Chill Dragon Fruit D9 Gummies:

  • Balanced Formulation: Each gummy contains a precise 1:1 ratio of 10mg Delta 9 THC and 10mg CBD, offering a harmonious blend for relaxation.
  • Tropical Flavor: Indulge in the tropical taste of dragon fruit, adding a delightful twist to your experience.
  • Vegan and Gluten-Free: Made with vegan-friendly and gluten-free ingredients, catering to diverse dietary preferences.
  • High Potency: Formulated as a new feature in our high mg THC product lineup, providing potent relief.
  • Quality Assurance: Rigorously tested for purity, potency, and safety, ensuring premium quality backed by third-party lab testing.

“We recognize that we have a diverse customer base and some individuals may experience negative side effects with high THC consumption. We were driven to create a product designed to mitigate these effects, targeting a more mellow and tranquil state of mind,” continued Kennedy. “Our dedication to providing a premium experience extends to prioritizing our customers’ well-being, and we’re proud to offer a product that not only delivers on potency but also promotes a positive and enjoyable experience just in time for Summer.”

cbdMD’s Max Chill Dragon Fruit D9 Gummies retail for $39.99 and are available for purchase at www.cbdmd.com. Must be 21 years or older to purchase. For more information about cbdMD, please visit cbdmd.com or engage with us on social at @cbdmd.usa.

About cbdMD, Inc.:

cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport® products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD’s products.

Forward-Looking Statements:

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to federal and state CBD regulation, and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO
+1 (704) 445-3064
IR@cbdmd.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209458

Staff

Recent Posts

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today…

38 minutes ago

Mexico’s EHR Revolution: Driving Digital Health Innovation and Market Growth, Insights From Black Book Research

Key Trends, Vendor Performance, and Opportunities Transforming Mexico's Healthcare IT Landscape MIAMI, FLORIDA / ACCESSWIRE…

38 minutes ago

Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees

Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

4 hours ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology…

4 hours ago

Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out

PITTSBURGH, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused…

4 hours ago

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

7 hours ago